Notable 52-Week Highs and Lows of the Day 06/23: (BMY) (CV) (ZAGG) High; (AUO) (NSPH) Low

This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.

52-Week High:

• Bristol-Myers Squibb Company (NYSE: BMY) high of $29.54. Bristol-Myers Squibb having a great day after reporting that ELIQUIS met the primary efficacy objective of non-inferiority to warfarin on the combined outcome of stroke (ischemic, hemorrhagic or unspecified type) and systemic embolism in a recent Phase 3 ARISTOTLE trial. In addition, ELIQUIS met the key secondary endpoints of superiority on efficacy and on ISTH (International Society on Thrombosis and Haemostasis) major bleeding compared to warfarin. Shares moved 6.5 percent to the new high on the session. Bristol-Myers Squibb was also upgraded at Morgan Stanley and Atlantic Equities. Notably, Pfizer's pretty darn close to hitting a new 52- week high as well, shares reaching $20.96 intraday, compared to the high of $21.45.
  
  
• Central Vermont Public Service (NYSE: CV) high of $35.88. Central Vermont reports the receipt of an unsolicited takeover offer. Its Board is currently reviewing the deal. Central Vermont is currently in a merger agreement with Fortis Inc.
  
  
• ZAGG Incorporated (Nasdaq: ZAGG) high of $15.85. After closing over 18 percent better yesterday, ZAGG is seeing continued momentum upon word of an acquisition of iFrogz for $105 million. Volume on the move today is also about three-times normal.
  
  
• Genesco Inc. (NYSE: GCO) high of $50.63. Genesco reports the acquisition of Schuh Group Ltd. for £100 million. Shares moved over 12 percent higher to the new mark today.

52-Week Low:

• AU Optronics Corp. (NYSE: AUO) low of $6.60. Not making a substantial move lower today, AU Optronics is actually rebounding off of days' lows. The stock, like others, was the victim of initial selling at the start of the session today. Increased jobless claims, however, might lead to fewer purchases of AU Optronics products.
  
  
• Nanosphere, Inc. (Nasdaq: NSPH) low of $1.46. Initial selling stemming from market conditions allowed Nanosphere to hit a new low today. Yesterday, Nanosphere is continuing lower from yesterday, after updating on its premarket approval application following the FDA issuance of a not approvable letter for the Verigene Clopidogrel Metabolism Nucleic Acid Test (Plavix Metabolism). The Company believes the deficiencies cited in the FDA letter are resolvable and ultimately the PMA for the Plavix Metabolism test will be approved by the FDA, although there can be no assurance of such approval.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
• Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
• After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home